Technology platform serving also for external screening projects

The FMP hosts the central technology platform of the ChemBioNet and NDDD network, the Screening Unit, which has been established for systematic screening of large compound libraries for bioactive small molecules modulating biological networks. The Screening Unit also manages the technology platform of the Max-Delbrueck-Centrum for Molecular Medicine (MDC) and Berlin Institute for Medical Systems Biology for genome-wide RNA-interference used for Systems Biology in C. elegans and in human cell lines.

The Screening Unit manages the central compound collection of the German Initiative for Chemical Biology, ChemBioNet, which encompasses about 50,000 substances so far. Thereof, 17.000 commercially available compounds have been chosen by the FMP in cooperation with the Max-Delbrück-Centrum für Molekulare Medizin Berlin-Buch (MDC), the Helmholtz-Zentrum für Infektionsforschung (HZI), and the Biotechnology Centre of Oslo, University of Oslo according to the guidelines of the World Drug Index (WDI). Another 20.000 compounds originate from the FMP and the Combinature Biopharm AG. Next to small molecule libraries, the FMP serves customised peptide libraries. The project oriented chemical synthesis and optimisation of small molecules is supported by medicinal chemists, drug modellers and structural biologists of the institute on the basis of individual cooperations.

Visit the Screening Unit Website: Screening (at) FMP - fmp-berlin.de